Targets › PDK1
1 program from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Metabolic and endocrine, Oncology.
Kinase that plays a key role in regulation of glucose and fatty acid metabolism and homeostasis via phosphorylation of the pyruvate dehydrogenase subunits PDHA1 and PDHA2. This inhibits pyruvate dehydrogenase activity, and thereby regulates metabolite flux through the tricarboxylic acid cycle, down-regulates aerobic respiration and inhibits the formation of acetyl-coenzyme A from pyruvate. (UniProt, Q15118)
Open in Phaseline: the race on PDK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Saol Therapeutics | Sodium Dichloroacetate Pyruvate dehydrogenase kinase inhibitor | PDK2, PDK3, PDK4, PDK1 | Phase 3 | Pyruvate Dehydrogenase Complex Deficiency; Glioblastoma Multiforme | – |
Pyruvate Dehydrogenase Complex Deficiency (1) Glioblastoma Multiforme (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.